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Aims: Registries have the potential to capture treatment practices and outcomes in populations 
beyond the constraints of clinical trial settings. The value of data obtained depend critically upon 
robust quality standards (including source data verification [SDV] and training); features that are 
absent from registries. This paper outlines the quality standards developed for Global 
Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF). Methods and 
results: GARFIELD-AF comprises ~57,000 patients prospectively recruited over 6.5 years in 35 
countries in five successive cohorts. The registry employs a combination of remote and onsite 
monitoring to ascertain completeness and accuracy of records and by design, SDV is performed 
on 20% of cases (i.e. ~11,400 patients). Four performance measures for ranking sites according 
to data quality and other performance indicators were evaluated (including data quality for 13 
quantifiable variables, late data locking, number of missing critical variables, and history of poor 
data quality from the previous monitoring phase). These criteria facilitated the identification of 
sites with potentially suboptimal data quality for onsite monitoring. During early phases of the 
registry, critical variables for data checking were also identified. SDV using these variables 
(partial SDV in 902 patients) showed similar concordance to SDV of all fields (110 patients): 
94.4% vs 93.1%, respectively. This standard formed the baseline against which ongoing quality 
improvements were assessed, facilitating corrective action on data quality issues. In 
consequence, concordance was improved in the next monitoring phase (95.6%; n=1172).  
Conclusion: The quality standards in GARFIELD-AF have the potential to inform a future 
“reference” for registries. 
Clinical Trial Registration: NCT01090362 





































































Atrial fibrillation (AF) is highly prevalent, especially in aging populations, and is currently 
estimated to affect approximately 5–6.1 million people in the US and 8.8 million people in 
Europe.(1-4) AF and its complications constitute a major public health burden and account for 
US$16–26 billion of the annual US health expenditure,(5) and at least 1% of the National Health 
Service budget in the UK (US$2.3 billion).(6) To optimize management of the condition, robust 
multinational observational programs are needed to characterize patients with AF, their 
management and their outcomes. 
 
Several large-scale national and international registries are under way, with the aim of defining 
the management and outcomes in broadly representative populations of patients with AF, 
including: GARFIELD-AF (clinical trial identifier: NCT01090362), GLORIA-AF 
(NCT01468701), ORBIT-AF (NCT01701817) and PREFER in AF.(7-11) These observational 
registries have the potential to capture the burden of disease in large-scale populations(12) by 
employing wide inclusion criteria and representation of historically under-researched groups, 
such as the elderly and patients with comorbidities.(13)  
 
However, registries differ in their design, recruitment strategies, care settings, geographic 
representation and duration of follow-up. Only some registries collect data prospectively and 
employ systematic quality assurance methods to check the validity of data against sources, and 
use independent adjudication to ensure the robustness of outcome and safety measures. Thus, to 
allow robust interpretations, there is a compelling need for appropriate quality standards to be 




































































Evidence generated from multisite randomized controlled trials (RCTs) is recognized as the 
“gold standard” for comparing treatment options. Such trials employ robust methods for 
comparing treatment strategies, but they have restrictive inclusion/exclusion criteria,  which is a 
form of entry bias since eligibility for both forms of therapy is mandatory in order to ethically 
justify randomization.(14) Hence, trial patients do not necessarily reflect the full range of 
baseline characteristics, nor the frequency of outcome and safety events observed in unrestricted 
“real-world” populations.   
 
The study design also needs to be appropriate for the research questions. While the processes 
employed in RCTs may represent the appropriate quality standards and performance measures 
for comparing treatments for product registration, these measures are not designed for large-scale 
observational registries.  Nonetheless quality standards and performance measures are required 
for registry programs, but these are not well defined, and can differ substantially from one 
program to the next.  
 
Source data verification 
The International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guideline 
defines trial monitoring as “the act of overseeing the progress of a clinical trial and of ensuring 
that it is conducted, recorded and reported in accordance with the protocol, Standard Operating 
Procedures, GCP, and the applicable regulatory requirement(s)”.(15) ICH GCP does not specify 
the methods for monitoring but suggests that “in general there is a need for on-site monitoring, 





































































One of the most common procedures undertaken during onsite monitoring is source data 
verification (SDV), in order to check that data recorded within electronic case report form 
(eCRF) matches the primary source data. Such quality standards in registries are key to the 
veracity of the findings and their generalizability. However, the extent of SDV varies and some 
registries and observational programs avoid SDV completely, as it is considered too intrusive 
during the collection of real-world data. Post-marketing surveys, for example, tend not to use 
SDV, and instead opt for risk-management approaches, relying entirely on the results of remote 
monitoring to check data reliability and to trigger onsite management and training.   
 
Comprehensive (i.e. 100%) SDV of the whole record for all patients, as performed in RCTs 
designed for product registration, is impractical and beyond the financial scope of large-scale 
registries. More cost-effective alternatives to 100% SDV are needed for registries.(16-18) A few 
registries have adopted a combination of remote monitoring and risk-based onsite audits and 
SDV to ensure that data aligned to routine practice are correctly reported according to the study 
protocol.(19, 20)  
  
Recording of data and quality assurance 
A criticism of registries is that they may lack the stringent quality assurance, as seen for key 
safety and efficacy endpoints in clinical trials. What constitutes “acceptable” data quality for a 
given clinical trial or registry depends on multiple factors, including the variables themselves, 
the size of the dataset, the type and extent of errors, and the accuracy of the statistical 
analysis.(21) The quality of data is frequently assessed centrally using Kappa summary statistics 




































































error rate of 5% or less within electronic datasets(22)  and outstanding queries on 1% or less of 
the data are generally considered acceptable standards.(16, 23) Are the same standards 
achievable and appropriate for registries? 
 
Data management and remote monitoring 
In order to mitigate the risks of reduced data quality, large studies are increasingly dependent on 
remote monitoring and quality assurance. Data discrepancies that are identified by remote 
adjudication can be queried in “data management” processes that involve the application of 
screening rules and internal consistency checks. In large registries, achieving a balance between 
data integrity and ease of enrollment and follow-up is an important consideration during the 
planning of audits.   
 
Quality assurance protocols 
Internal data quality assurance protocols are needed to assess completeness, consistency and 
accuracy.(24) However, registries vary in their quality assurance procedures. There are key 
differences between registries that employ routinely collected data (with variable clinical 
interpretations of endpoints and bleeding events) versus those with predefined endpoints, which 
are adjudicated and audited for accuracy.(25) Large-scale epidemiological studies are valuable, 
but they do not collect all the variables needed in assessing treatments and outcomes in patients 
with AF and instead rely on routinely collected clinical data with neither standardized definitions 





































































With the absence of a consensus, and only limited discussion in the literature of a reasonable and 
cost-effective approach for the audit of registry data,(28, 29) the authors reflected on how they 
might achieve the quality standards and performance measures within large-scale registries such 
as the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF). This 
paper outlines the quality standards that were developed for the ongoing GARFIELD-AF 
registry, and derivation and validation of an electronic data quality score for study sites so that 
risk-based SDV could be implemented. 
 
GARFIELD-AF REGISTRY DESIGN 
A detailed description of the design of the GARFIELD-AF registry has been reported 
previously.(7) In brief, GARFIELD-AF is an ongoing non-interventional registry of adults (≥18 
years) with newly diagnosed non-valvular AF (diagnosis was established within 6 weeks of 
enrollment) and with one or more additional risk factor for stroke, as judged by the investigator, 
regardless of therapy. These risk factors were not prespecified in the protocol, nor were they 
limited to the components of existing risk stratification schemes. Prospective enrollment of 
consecutive patients meeting the inclusion criteria began in March 2010 in 19 countries 
worldwide. The roll-out of the GARFIELD-AF registry across five phases (cohorts) has now 
extended to 35 countries and more than 50,000 patients have been recruited, prospectively, over 
6.5 years. The follow-up period will be a minimum of 2 years and a maximum of 8 years.  
 
GARFIELD-AF is an independent academic research initiative sponsored by the Thrombosis 
Research Institute (London, UK) and supported by an unrestricted research grant from Bayer 




































































AF registry are subject to independent review by an Audit Committee which, in turn, reports to 
the scientific Steering Committee. The statistical analyses are conducted by the Thrombosis 
Research Institute and independently reviewed by a leading statistician from a North American 
academic research center (KP).   
 
The primary aim of the registry is to define initial and ongoing management strategies and 
clinical and economic outcomes in patients with non-valvular AF in the clinical practice (non-
trial) setting. The key outcomes for the registry are all-cause mortality, stroke or systemic 
embolism, major bleeding and healthcare utlization (including any hospitalization, emergency 
department visit, etc.). Data capture the management of AF from the time of diagnosis to the end 
of follow-up from sites, which have been selected randomly from a representative sample of 
different care settings in each participating country (office-based practice; hospital departments – 
neurology, cardiology, geriatrics, internal medicine, and emergency; anticoagulation clinics; and 
general or family practice).   
 
THE AUDIT PROCESS 
Central and onsite data monitoring  
The registry employs a combination of remote electronic monitoring and more conventional 
onsite monitoring (including SDV) at approximately 10% of sites. The milestones for study 





































































Quality standards for the GARFIELD-AF registry 
Quality standards for the GARFIELD-AF registry, as defined by the protocol, are summarized in 
Table 1. Sites are given access to online data entry only after formal training; all sites receive 
regular re-training depending on site performance and have ongoing access to a training web 
portal. In addition, 20% of all eCRFs (i.e. ~11,400 of 57,000 patients) are monitored against 
source documentation during six phases of audit between 2010 and 2018 (Fig. 1). All 
modifications to the data are recorded electronically in an audit trail. At study completion, 5% of 
data for each of the critical variables for baseline data and follow-up (as defined in Appendix 
Table 1) are audited during the statistical analysis.    
 
The eCRFs are monitored remotely to check for consistency, to identify implausible and outlying 
data, evaluate data quality and completeness, and to analyze patterns and trends. Monitoring and 
tracking of site-specific issues occurs either on a monthly, quarterly or 6-monthly basis, 
depending on the performance of each site. Site-level performance data, including patient 
recruitment numbers and rate of recruitment, are recorded by the clinical research associate 
(CRA) who also ensures query resolution and data locking (of baseline data and 4-monthly 
intervals thereafter); data are reviewed and audited at 12-monthly milestones. As outlined in Fig. 
1, the number of patients targeted for onsite monitoring during each phase of the audit is 
proportional to the number of patients recruited into the trial at the time of audit. The number of 
audited patients’ records is cumulative over time so that by the end of the study, 20% or ~11,400 





































































SDV of critical variables 
Electronic data capture allows large volumes of data to be analyzed concurrently and to produce 
the summary statistics (e.g. missing data, data error rates, protocol violations) in real time in 
order to assess the magnitude of discrepancies between the electronic records and the site-
verified source data.   
 
The most efficient processes for onsite monitoring (in order to achieve 20% SDV of cases) 
evolved over several phases of monitoring. The process of onsite monitoring started early in the 
study, with an evaluation of 10 sites recruiting patients into cohort 1 (C1) in two countries (UK 
and France). Onsite monitors conducted 100% SDV of all fields in 15 patients (1–2 at each site). 
On average, a complete SDV (i.e. 100% SDV) of all fields took 8–10 hours to perform for each 
patient record. This first phase was both labor- and time-intensive and it led to revision of the 
monitoring strategy. 
 
Complete versus partial SDV  
During phase II monitoring, an abridged SDV process involving the assessment of only variables 
that were critical to the clinical dataset and statistical analyses was developed (see Appendix 
Table 2). Overall, 110 sites were monitored during phase II from 24 countries between 
November 2013 and April 2014. Eighty percent of the 110 sites were selected using 
performance-related criteria (data quality, GCP compliance issues, patient enrollment, outliers 
and other statistical anomalies) and approximately 20% of sites (which served as a control) were 





































































 In order to compare complete SDV with partial SDV, complete SDV was conducted in the first 
randomly selected patient at each site (i.e. 10% of patients) and compared with partial SDV of 
critical variables for nine patients at each site (i.e. ~90% of patients); SDV was only conducted 
on fields that were relevant to the patient or analysis at the time of study. Assessment of the 
results across all 110 sites showed that the level of concordance between the source data and the 
eCRF was similar following both complete SDV (93.1% of 7259 fields in 110 of 1012 patients) 
and partial SDV of critical variables (94.4% of 15,272 fields in 902 of 1012 patients), thus 
supporting the validity of partial SDV.   
 
Risk-based site selection for onsite monitoring  
During phase III monitoring, ~104 of ~1040 (i.e. 10%) sites were scheduled for onsite 
monitoring. Consistent with phase II monitoring, the goal was to identify ~80 of 104 (~80%) 
sites with poor quality so that resources could be targeted for onsite monitoring and for partial 
SDV at sites where there were potentially the greatest problems. The remaining 20% of sites 
were randomly selected (and served as a control for comparison with the data from poor quality 
sites).   
 
An equal number of poorly performing sites (i.e. 4 × 20 = 80) were identified based on each of 
the following four complementary measures of data quality and other performance indicators: 
Data quality for 13 quantifiable variables within the eCRF (see Appendix Table 2): For each 
critical variable, the mean value across all patients at a site for that variable was assessed and, 
if it was not within the defined interval of ± 2 × standard error of the mean, then the site was 




































































depending on the number of “out of control” flags. All sites were then ranked according to 
the data quality score and approximately 20 (i.e. one-quarter of 80 sites) of the worst 
performing sites were selected for onsite monitoring. 
Late locking of data: A site was designated a late lock score if late data locking occurred 
more than 30% of the time for the key milestones (i.e. baseline, 12 months and 24 months). 
Approximately 20 sites with the highest proportion of late-lock defaults were selected for 
onsite monitoring.  
Total number of missing critical events: Sites were given a score proportional to the number 
of critical missing events. Missing events were identified by the data discrepancy between 
the event summary page of the eCRF and the completed events in the eCRF for each of the 
patients. Approximately 20 sites were selected for onsite monitoring on this basis. 
The findings (GCP critical and SDV discrepancies) during the previous monitoring phase. 
GCP (non-compliance) findings were weighted for each site as either “critical”, “major” or 
“minor” and the 20 sites with the highest default scores were selected for onsite monitoring. 
Based on the findings from these analyses, the poorest performing 78 sites from each component 
of the score were selected and 26 sites were also randomly selected for onsite monitoring. There 
was some overlap in the sites selected by the above measures: three sites selected for the missing 
event score were also selected by the 13-item score, the late data locking score and the GCP 
compliance score.  For a minority of sites (approximately 5%) that were unable or unwilling to 
participate in the audit, replacement sites were identified.   
 
In total, 1172 patients at 104 sites (9.9% of the total of 1046 sites) with potential poor data 




































































2015 during phase III of the monitoring process. The distribution of sites by country is 
summarized on the horizontal axis of Fig. 3. 
 
Testing data quality at the sites selected for onsite monitoring 
The effectiveness of this site selection process was assessed by comparing the error rate (based 
on partial SDV) in patients at sites selected using each of the individual components of the site 
selection process. The results showed that the error rate based on partial SDV was greater in 
patients at sites selected using the 13-item score (7.1% [95% confidence interval {CI}: 6.0% to 
8.2%] of 2031 fields in 144 patients) compared with patients from sites selected with late locking 
(error rate: 4.4% [95% CI: 3.5% to 5.3%] of 2069 fields in 91 patients) or those selected for total 
number of missing events (error rate: 3.2% [95% CI: 2.8% to 3.7%] of 5771 fields in 185 
patients). The 13-item score (which provided an indicator of potential outliers in the dataset) was 
the most effective in identifying sites with poor data quality (based on partial SDV), with an 
error rate almost twice the average rate observed at the remaining sites (7.1% vs 3.7%). 
 
AUDIT RESULTS FOR KEY QUALITY ASSURANCE PERFOFMANCE MEASURES  
Concordance with source data  
The process for phase III monitoring (which included partial SDV of critical variables) enabled 
many more patients’ records and fields to be verified during phase III (92,507 fields overall in 
1172 patients) than during phase II (37,243 fields in 1012 patients) (Table 2). Even though a 
greater number of patients were identified from sites with poor data quality in phase III, the level 
of concordance was similar in both phases – eCRFs matched patient records 94.0% of cases in 




































































all sections of the eCRF in phase II and phase III, except for two sections of the eCRF where 
concordance was below 90%. These were “hospitalization/procedure/consultation” (89.3%) and 
“treatment change/interruption” (80.8%), in phase II. The concordance between source data and 
the eCRF for the “hospitalization/procedure/consultation” section was substantially improved in 
phase III (97.2%); this was attributed, in part, to the improved training of sites following phase 
II. The proportion of cases where source data were not available decreased from 12.1% in phase 
II to 2.8% in phase III. Missing source data were attributed, in some cases, to legal and 
administrative restrictions and, in other cases, to the unpreparedness of patient records at the site 
due to the short notice prior to onsite visits. There was no indication that the eCRF had been 
completed in the absence of source data. 
 
Concordance with source data was similar in all geographic regions during the monitoring in 
both phase II (Americas 96.7%; Asia-Pacific 94.9%; Europe, the Middle East, and Africa 
[EMEA] 95.3%) and phase III (Americas 94.9%; Asia-Pacific 95.1%; EMEA 95.9% Phase III).  
Comparison of concordance by country (Fig. 3) identified some countries where there was a 
notable deviation from the protocol in the recording of data. In some countries, this discrepancy 
was attributed to the low number of sites in the registry at the time of phase III monitoring. 
 
Monitoring of missing events  
The monitoring of missing events (i.e. events recorded in the source data but not in the eCRF) 
found that the number of missing events was low and diminished from phase II to phase III. 




































































identified as missing in 1012 patients.  During phase III monitoring, 10 bleed events, 3 stroke 
events and 12 deaths in 1172 patients were identified as missing and the eCRFs updated.   
   
Missed hospitalization events were also frequent during phase II monitoring (350/1156 [30.3%]), 
but less frequent in phase III (402/2288 [14.9%]) in the worst performing sites and randomly 
selected sites (138/842 [16.4%]). These missing events were predominantly due to sites 
recording only AF-related hospitalizations. Following this finding, the coordinating center 
(Thrombosis Research Institute, London, UK) provided additional training to all sites.  
Additional onsite monitoring of poor performing sites was also performed in order to ensure that 
the recording of data on key endpoints (stroke, all-cause mortality, bleeding) was adequately 
addressed.  To assess the impact of training, further audit of missing events at poorly performing 
sites will also be captured in the next audit phase.  
 
Other GCP findings 
In phase II, most of the findings identified in a subset of 30 out of 110 sites related to use of the 
incorrect version of the informed consent form (ICF). At two sites (in five patients), the missing 
ICF was not recovered from the patients’ files. These five patient records were not included the 
database and the related data were not analyzed. In phase III, most of the discrepant findings at 
31 of 104 sites were also related to use of the incorrect version of the ICF. One finding was 
related to a site breach of eligibility criteria and five to breaches of the GCP informed consent 
process. As a part of the Corrective Action Preventative Action (CAPA), the patient data were 
excluded from the analyses for these records. The site staff have received retraining in the 






































































The overall objectives of the audit process in GARFIELD-AF were to: evaluate the compliance 
of the protocol with GCP and local regulations, the quality and completeness of data and source 
documentation, and the concordance between eCRF data and source documents, and to identify 
potentially unreported outcome events of interest.  
 
Whereas standards for the design and conduct of large-scale randomized trials have evolved and 
gained acceptance,(30) registries and observational datasets vary substantially in their design, 
their conduct, the extent to which they utilize routinely reported data, and the extent to which 
they audit and validate outcome and safety data.(28) Some registry and observational programs 
employ retrospective data derived from routinely collected information. In such retrospective 
programs there are key challenges, including the variability in defining clinically recorded 
outcomes, inconsistency of recording of baseline characteristics and outcome measures, and 
uncertain or absent verification of key data. Prospective registries with predefined baseline 
characteristics and outcome measures and with defined quality standards have the potential to 
provide more robust datasets. 
 
There have been attempts to establish key criteria for the validity of registries,(31) but as yet, no 
consensus exists. However, independent reviewers have proposed a number of key criteria to 
help establish the validity of registries and their interpretation (see Table 3).(29) The extent to 
which large-scale registries and observational studies fulfill these criteria varies substantially and 




































































Committee has reviewed these criteria in the GARFIELD-AF program12,13 and has determined 
that the registry meets these criteria. In addition, the committee has implemented further quality 
standards (See Appendix Table 3). 
 
Complete SDV in registries is neither practical nor cost-effective. Published studies have shown 
that only a very small percentage of data is changed due to SDV of all fields within a record, and 
the effect of this change on the primary analysis is minimal.(16, 18, 32) Robust sampling 
strategies with SDV of up to 20% of records may be sufficient, without clinically significant 
differences in the primary analysis.(22) In the audit of GARFIELD-AF data, we found that there 
was a similar level of concordance for SDV of whole records compared with SDV of the critical 
variables.  During onsite monitoring, for the 9.9% of the poorest sites in terms of data quality 
(derived according the GARFIELD-AF data quality score), <5% discrepancies between the 
electronic records and the site-verified source data were found during phase III monitoring. This 
is considered to be within the acceptable bounds in the field of clinical trials for regulatory 
approval. Houston et al.(22) recently determined that an error rate of 5% or less within electronic 
datasets for RCTs should be the “gold standard” for determining data quality within a clinical 
setting. The GARFIELD-AF registry met this standard. Where data quality issues were identified 
in certain countries and centers, early corrective action including onsite training (improved 
knowledge of the data management system) and further clarification of the eCRF ensured 
ongoing quality improvements (for example, to ensure that data on all-cause hospitalizations 
were appropriately captured at all sites).  Regular audit, annual deadlines for data locks and 
additional onsite monitoring of poorly performing sites in between audits has also been an 




































































submitted for publication from GARFIELD-AF are based only on locked data where efforts are 
made to ensure that all events are captured; while the data presented in this paper include 
information on interim data (i.e. “unlocked” data where either the whole, or part, of the eCRF 
data were not finalized). 
 
In summary, no single monitoring approach is applicable to all studies. The frequency and extent 
of monitoring need to be appropriate, and achieve a balance between reliable data integrity and 
ease of enrollment and follow-up.  Audit approaches should be tailored to the objectives of the 
study and may combine a number of different monitoring methods that allow cost-effective and 
real-time trend analysis. GARFIELD-AF adopted a dual auditing scheme using remote 
monitoring as well as onsite monitoring targeted at sites with potential suboptimal quality data. 
This approach may be useful for other large-scale registries. The GARFIELD-AF sets high 
standards for a large-scale registry (summarized in Table 1). Starting early in the recruitment of 
patients into the registry, eight audits were planned across all phases of the recruitment and 
monitoring so that by the end of the study, 20% of all eCRFs will have been monitored (Fig. 1). 
Only critical variables that are considered essential to overall data quality are assessed during 
SDV. For example, in GARFIELD-AF, baseline characteristics important to the research 
question (such as components of the CHA2DS2-VASc score for assessing the risk of stroke) and 
outcomes (stroke, bleeding events and death) are audited. Audits should be followed by feedback 
and training, then reassessment. In GARFIELD-AF, the results of the previous audit is used to 
facilitate corrective action on data quality issues and forms a baseline against which quality 
improvements are assessed in the next monitoring phase. All sites receive regular re-training 




































































intervals, results are reported to the steering and audit committees to ensure proper oversight and 
management of the study. Finally, national data are also fed back to sites to incentivize the 
ongoing recruitment and/or follow-up of patients.  Through the implementation of the standards 
outlined in Table 1, we believe that GARFIELD-AF has the potential to inform a future 
“reference standard” for the successful delivery of high-quality data from registries. 
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Table 1. Quality standards for the GARFIELD-AF registry 
 Audits are conducted at regular intervals, starting early during the recruitment phase and 
continuing until the end of follow-up, thereby allowing cost-effective and real-time trend 
analysis across the whole study.  
 Audits include remote monitoring as well as onsite monitoring targeted at sites with 
potential suboptimal quality data.   
 Sites with potential suboptimal quality data are identified using the following four 
performance measures for: data quality (using quantifiable variables), late data locking, 
number of missing critical variables, and a history of poor data quality from the previous 
phase of monitoring.  
 The target for source data verification (SDV) is 20% of all records. Only critical variables 
that are considered essential to overall data quality are assessed.   
 Audit is followed by feedback and training, then reassessment and additional onsite 
monitoring of poorly performing sites.   
 At each audit, 80% of sites with data quality issues are selected for onsite monitoring and 
the results compared with the quality of data at 20% of sites which are randomly selected.  
 All modifications to the data are recorded electronically in an audit trail.  
 An independent professional statistician and steering committee monitors the data 
collection and analysis.  
 Results are reported to the steering and audit committees at pre-agreed milestones to 
ensure proper oversight and management of the study.  
 Annually, national data are fed back to sites to incentivize the ongoing recruitment and/or 




































































 At study completion, 5% of the data for each of the critical variables for baseline data and 
follow-up are audited during the statistical analysis.    
 All sites receive training before the start of the study and regular re-training depending on 





































































Table 2. Summary of results for phase II and phase III of onsite monitoring (including source 
data verification) 
Variable Phase II Phase III 
Patients 1012 1172 
Sites 110 104 
Countries 24 28 
Source data not available 4475/37,243 (12.0) 2550/92,507 (2.8) 
Data verified (excluding blank fields) 21,178/27,006 (78.4) 29,121/33,005 (88.2) 
Data verified (excluding blank fields and source 
data not available) 
21,178/22,531 (94.0) 29,121/30,455 (95.6) 
Queries (excluding blank fields and source data 
not available) 
1065/22,531 (4.7) 1361/30,455 (4.5) 
*Source data were not available if information was added to the case report form that could not 
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Phase 4 – June2016
1850 Patients 
Phase 5 – Dec 2016
1850 Patients 
Phase 6 – April 2016
1850 Patients 
Phase 7 – Dec 2017
1850 Patients 


































































































































































































































































Figure 1. GARFIELD-AF recruitment, monitoring, and reporting milestones 
 
Figure 2. Audit results from phase II (1012 patients at 110 sites in 28 countries) and phase III 
(1172 patients at 104 sites in 35 countries) monitoring 
 
Figure 3. Country differences in concordance (based on partial source data verification of 






































































Appendix Table 1. Critical variables for source data verification 
Baseline: 
o Date of diagnosis 
o Date of consent 
o Gender 
o Date of birth 
o Demographics 
 Systolic blood pressure 
 Diastolic blood pressure 
o AF treatment initiated at diagnosis 
 AF treatment strategy initated 
 Cardioversion 
o Stoke prophylaxis 
 Antiplatelet drugs 
 Anticoagulant drugs 
 VKA medication 



































































 Dose frequency for oral direct thrombin inhibitors 
o Cardiovascular history focused on CHA2DS2-VASc components  
 Current cardiac condition 
 Congestive cardiac failure 
 Coronary artery disease 
 History of aortic or peripheral artery disease 
 Pulmonary embolism or DVT 
 Systemic embolization 
 Prior TIA 
 Prior stroke 









































































o Event summary 
 Event being entered  
 Reason for lost to follow-up (if applicable) 
o Treatment change 
 Stroke prophylaxis (as above for baseline) 
o Stroke/TIA 
 Date of event 
 Event type (TIA/stroke) 
 Type of stroke 
o Bleeding event 
 Date of event 
 Site of bleed 
 Severity of bleed 
 Outcome of bleed 
o Death 
 Date 
 Primary cause of death 


































































 Noncardiovascular cause of death 
o Hospitalization 
 Date of hospitalization 





































































Appendix Table 2. The 13 parameters identified from the eCRF as indicators of GARFIELD-AF data quality 
No. Patient-level indicator Site-level indicator 
1 The number of times the option ‘unknown’ is chosen Mean of patient-level indicator by site 
2 The number of times the option ‘none’ is chosen Mean of patient-level indicator by site 
3 The number of times the option ‘blank’ is chosen Mean of patient-level indicator by site 
4 The number of times the option ‘other’ is chosen Mean of patient-level indicator by site 
5 1 if patient has AF type ‘new’; 0 otherwise % of 1 in patient-level indicator by site 
6 1 if patients has ‘normal’ cardiac condition; 0 otherwise % of 1 in patient-level indicator by site 
7 1 if patient on VKA without INR reading; 0 otherwise % of 1 in patient-level indicator by site 
8 1 if bleeding event without severity; 0 otherwise % of 1 in patient-level indicator by site 
9 1 if patient has a stroke/TIA events without type of event; 
0 otherwise 
% of 1 in patient-level indicator by site 


































































11 Number of hospital admissions per patient Mean of patient-level indicator 
12 Number of bleeding events per patient Mean of patient-level indicator 
13 1 if lost to follow-up; 0 otherwise % of 1 in patient-level indicator by site 




































































Appendix Table 3. Recommended quality standards for large-scale registries29 
Standardized disease definitions employed and clearly stated in the methods section 
All sampling techniques standardized 
Randomized selection of hospitals or clinics strongly encouraged (note: community-wide data collection is even better) 
All participants have a clear understanding of the information being sought for each entry on the data sheet 
All collected data reported (note: the selection, or exclusion, of centers or data forms increases bias) 
All original data sheets or electronic submissions centralized. Analysis performed by a central data collection and analysis 
center 
A professional statistician monitors the data collection and analysis 
Each data sheet or electronic submission carefully examined by the central data center to ascertain completeness and accuracy. 
Individual investigators promptly queried concerning incomplete or confusing responses 
The registry protocol reviewed at each participating center by an institutional review board for studies involving human subjects 
The names of all participating investigators identified in the published report of the registry 
Sponsorship for the trial clearly stated in all published reports so that commercial bias can be easily identified 
One principal investigator, or a small steering committee, designated to maintain administrative order, adjudicate disagreements, 




































































































































Appendix: GARFIELD-AF Registry Investigators 
 
Global Steering Committee 
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